Metsera, Inc.
MTSR
Classement en actions
#2568
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Prix de l'action
$70.50
Dernière synchronisation: 2025-11-14
Capitalisation boursière
$7.33B
Changement (1 jour)
0.00%
Changement (1 an)
33.60%
Pays
US
Échange Metsera, Inc. (MTSR)
Catégorie
Healthcare
Historique du prix de l'action pour Metsera, Inc. (MTSR)
Prix de clôture le plus élevé : $72.34 le 2025-11-01
Prix de clôture le plus bas : $26.50 le 2025-01-01
Prix de clôture le plus bas : $26.50 le 2025-01-01
Historique du prix de l'action de Metsera, Inc. de 2025 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | -10.54% |
| 2025 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $534.12 | 25.25% |
US
|
|
| $231.12 | 760.78% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $880.75 | 8.18% |
NL
|
|
| $289.51 | 1.72% |
BE
|
